<?xml version="1.0" encoding="UTF-8"?>
<results title="funders">
 <result pre="a Preclinical Ferret Model LiuWen-Chun12NachbagauerRaffael1StadlbauerDaniel1SolórzanoAlicia1Berlanda-ScorzaFrancesco3García-SastreAdolfo124PalesePeter14KrammerFlorian1*AlbrechtRandy A.12*[], 1Department of Microbiology, Icahn" exact="School of Medicine" post="at Mount SinaiNew York, NYUnited States[], 2Global Health and"/>
 <result pre="York, NYUnited States[], 2Global Health and Emerging Pathogens Institute, Icahn" exact="School of Medicine" post="at Mount SinaiNew York, NYUnited States[], 3PATH USSeattle, WAUnited"/>
 <result pre="NYUnited States[], 3PATH USSeattle, WAUnited States[], 4Department of Medicine, Icahn" exact="School of Medicine" post="at Mount SinaiNew York, NYUnited States Edited by: Karl"/>
 <result pre="based on the influenza virus vaccine strains selected by the" exact="World Health Organization." post="Although current influenza virus vaccines induce protection against infection"/>
 <result pre="an animal model of influenza that was highlighted in the" exact="National Institute of Allergy and Infectious Diseases" post="(NIAID)'s strategic plan for the development of universal influenza"/>
 <result pre="9A). The Advisory Committee on Immunization Practices (ACIP) of the" exact="Centers for Disease Control and Prevention" post="(CDC) recently announced the re-inclusion of LAIV vaccines into"/>
 <result pre="and provide broader protection against influenza virus infection (48). The" exact="National Institute of Allergy and Infectious Diseases" post="(NIAID) recently published a position statement in which they"/>
 <result pre="manufacture of pandemic H5N1 split virus vaccine, were provided by" exact="GlaxoSmithKline" post="(GSK). The cH5/1Cal09N1Cal09 (cH5/1) IIV is composed of an"/>
 <result pre="pDZ plasmids for the virus rescue were cloned at the" exact="Icahn School of Medicine at Mount Sinai" post="(ISMMS) as our previous study described (19). cH8/1 LAIV"/>
 <result pre="plasmids for the virus rescue were cloned at the Icahn" exact="School of Medicine" post="at Mount Sinai (ISMMS) as our previous study described"/>
 <result pre="seed virus was rescued by reverse genetics at the US" exact="Centers for Disease Control and Prevention" post="(52) and produced at ISMMS. The composition of recombinant"/>
 <result pre="the Institutional Animal Care and Use Committee (IACUC) of the" exact="Icahn School of Medicine at Mount Sinai" post="(ISMMS). Author Contributions W-CL, RN, DS, FK, and RA:"/>
 <result pre="Institutional Animal Care and Use Committee (IACUC) of the Icahn" exact="School of Medicine" post="at Mount Sinai (ISMMS). Author Contributions W-CL, RN, DS,"/>
 <result pre="are inventors in patent applications filed and owned by the" exact="Icahn School of Medicine at Mount Sinai" post="regarding influenza virus vaccines. The remaining authors declare that"/>
 <result pre="inventors in patent applications filed and owned by the Icahn" exact="School of Medicine" post="at Mount Sinai regarding influenza virus vaccines. The remaining"/>
 <result pre="USDA for virus pathotyping. Furthermore, we thank the team at" exact="PATH" post="for help with the coordination of the project. Funding."/>
 <result pre="of Influenza Virus Research and Surveillance (CEIRS) contract HHSN272201400008C, and" exact="PATH" post="(GAT.1878-01162340-COL). This study was also partly funded by a"/>
</results>
